Corey Carter

1.2k total citations
24 papers, 417 citations indexed

About

Corey Carter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Corey Carter has authored 24 papers receiving a total of 417 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Corey Carter's work include Lung Cancer Treatments and Mutations (8 papers), Epigenetics and DNA Methylation (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Corey Carter is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Epigenetics and DNA Methylation (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Corey Carter collaborates with scholars based in United States, Spain and France. Corey Carter's co-authors include Bryan Oronsky, Tony Reid, Arnold L. Oronsky, Neil Oronsky, Michelle Lybeck, Susan J. Knox, Pedro Cabrales, Scott Caroen, Giuseppe Giaccone and Ronan J. Kelly and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Corey Carter

23 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Corey Carter United States 11 161 147 144 84 71 24 417
Silke Gronau Germany 10 160 1.0× 135 0.9× 72 0.5× 65 0.8× 57 0.8× 14 368
Sulsal Haque United States 6 148 0.9× 168 1.1× 62 0.4× 50 0.6× 58 0.8× 15 346
Jadzia Tin-Tsen Chou Poland 6 150 0.9× 157 1.1× 70 0.5× 60 0.7× 97 1.4× 15 421
Yuansheng Duan China 13 109 0.7× 231 1.6× 46 0.3× 64 0.8× 42 0.6× 33 402
Marisol Miranda Galvis United States 9 144 0.9× 89 0.6× 52 0.4× 48 0.6× 70 1.0× 28 319
Melisa W-Y. Ho United States 5 193 1.2× 255 1.7× 130 0.9× 60 0.7× 63 0.9× 10 586
Huarong Tang China 12 116 0.7× 118 0.8× 113 0.8× 128 1.5× 17 0.2× 36 354
Kevin Furlong United States 6 207 1.3× 103 0.7× 77 0.5× 75 0.9× 24 0.3× 14 381

Countries citing papers authored by Corey Carter

Since Specialization
Citations

This map shows the geographic impact of Corey Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corey Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corey Carter more than expected).

Fields of papers citing papers by Corey Carter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corey Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corey Carter. The network helps show where Corey Carter may publish in the future.

Co-authorship network of co-authors of Corey Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Corey Carter. A scholar is included among the top collaborators of Corey Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corey Carter. Corey Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Durán-Pacheco, Gonzalo, G. Scott Chandler, Vidya Maiya, et al.. (2024). Correlation of safety and efficacy of atezolizumab therapy across indications. Journal for ImmunoTherapy of Cancer. 12(11). e010158–e010158. 3 indexed citations
2.
3.
Powles, Thomas, Zoe J. Assaf, Viraj Degaonkar, et al.. (2023). Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 85(2). 114–122. 61 indexed citations
4.
Inman, Brant A., Noah M. Hahn, Kelly Stratton, et al.. (2023). A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology. 6(3). 313–320. 21 indexed citations
5.
Oronsky, Bryan, et al.. (2020). Just eat it: A review of CD47 and SIRP-α antagonism. Seminars in Oncology. 47(2-3). 117–124. 63 indexed citations
6.
Carter, Corey, et al.. (2020). Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).. Journal of Clinical Oncology. 38(15_suppl). e15119–e15119. 5 indexed citations
7.
Bouvet, Michael, et al.. (2019). Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford Medical Case Reports. 2019(11). 461–463. 10 indexed citations
8.
Oronsky, Bryan, Sharad Goyal, Michelle M. Kim, et al.. (2018). A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Translational Oncology. 11(3). 771–778. 75 indexed citations
9.
Biswas, Romi, Shaojian Gao, Xu Zhang, et al.. (2017). P2.01-041 Integrated Proteo-Genomics Analyses Reveal Extensive Tumor Heterogeneity and Novel Somatic Variants in Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(1). S810–S811. 1 indexed citations
10.
Brzezniak, Christina, Mary Quinn, Bryan Oronsky, et al.. (2017). P2.06-031 QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets. Journal of Thoracic Oncology. 12(1). S1090–S1091. 1 indexed citations
11.
Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2017). P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 12(1). S1159–S1159. 5 indexed citations
12.
Summers, Thomas A., Corey Carter, Jan Scicinski, et al.. (2017). Abstract 966: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis. Cancer Research. 77(13_Supplement). 966–966. 2 indexed citations
13.
Wakelee, Heather A., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology. 11(10). S209–S210. 3 indexed citations
14.
Reid, Tony, George A. Fisher, Corey Carter, et al.. (2016). Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET. Cancer Research. 76(2_Supplement). B26–B26. 1 indexed citations
15.
Oronsky, Bryan, Jan Scicinski, Tony Reid, et al.. (2016). RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.. PubMed. 21(116). 251–65. 22 indexed citations
16.
Oronsky, Bryan, Corey Carter, Arnold L. Oronsky, et al.. (2016). Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. Oncotarget. 7(8). 9041–9045. 5 indexed citations
17.
Oronsky, Bryan, Jan Scicinski, Michelle M. Kim, et al.. (2016). Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules. 6(3). 32–32. 10 indexed citations
18.
Oronsky, Bryan, Arnold L. Oronsky, Michelle Lybeck, et al.. (2015). Episensitization: Defying Time’s Arrow. Frontiers in Oncology. 5. 134–134. 32 indexed citations
19.
Scicinski, Jan, George A. Fisher, Corey Carter, et al.. (2015). The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology. 5. 422–422. 15 indexed citations
20.
Kelly, Ronan J., Corey Carter, & Giuseppe Giaccone. (2010). Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab. Journal of Clinical Oncology. 28(28). e507–e510. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silke Gronau Breakdown of academic impact, for papers by Sulsal Haque Breakdown of academic impact, for papers by Jadzia Tin-Tsen Chou Breakdown of academic impact, for papers by Yuansheng Duan Breakdown of academic impact, for papers by Marisol Miranda Galvis Breakdown of academic impact, for papers by Melisa W-Y. Ho Breakdown of academic impact, for papers by Huarong Tang Breakdown of academic impact, for papers by Kevin Furlong
Rankless by CCL
2026